News
ONCO
1.190
+1.71%
0.020
Onconetix Shareholders Approve Flexible Reverse Stock Split Plan
TipRanks · 9h ago
Onconetix Inc. hielt Sonderversammlung ab
Reuters · 10h ago
Onconetix Inc. Held Special Shareholder Meeting
Reuters · 10h ago
Weekly Report: what happened at ONCO last week (0202-0206)?
Weekly Report · 21h ago
Weekly Report: what happened at ONCO last week (0126-0130)?
Weekly Report · 02/02 10:15
Weekly Report: what happened at ONCO last week (0119-0123)?
Weekly Report · 01/26 10:15
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 01/19 12:05
Weekly Report: what happened at ONCO last week (0112-0116)?
Weekly Report · 01/19 10:21
Weekly Report: what happened at ONCO last week (0105-0109)?
Weekly Report · 01/12 10:20
Weekly Report: what happened at ONCO last week (1229-0102)?
Weekly Report · 01/05 10:14
Weekly Report: what happened at ONCO last week (1222-1226)?
Weekly Report · 12/29/2025 10:14
ONCONETIX INC: FILES PROSPECTUS FOR RESALE OF 29.8 MLN SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING
Reuters · 12/22/2025 11:05
Weekly Report: what happened at ONCO last week (1215-1219)?
Weekly Report · 12/22/2025 10:14
Weekly Report: what happened at ONCO last week (1208-1212)?
Weekly Report · 12/15/2025 10:20
Onconetix Inc. Files Initial Statement of Beneficial Ownership for Director Sarah Romano
Reuters · 12/12/2025 23:05
Onconetix Approves CEO Bonus and Stockholder Proposals
TipRanks · 12/10/2025 22:29
Onconetix Inc. Held Annual Shareholder Meeting
Reuters · 12/10/2025 22:01
Onconetix Amends License Agreement with Labcorp
TipRanks · 12/10/2025 14:47
Proteomedix AG Launches PRIME Study Under Onconetix Inc
Reuters · 12/10/2025 14:28
Weekly Report: what happened at ONCO last week (1201-1205)?
Weekly Report · 12/08/2025 10:19
More
Webull provides a variety of real-time ONCO stock news. You can receive the latest news about Onconetix through multiple platforms. This information may help you make smarter investment decisions.
About ONCO
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.